DGAP-Media / 2020-05-18 / 10:04
The studies in the field of tinnitus research are extremely poor. An article
in the Medical Tribune Germany dated November 30, 2019 rightly complains
that too little research is being done in the area of tinnitus and that
patients feel let down by medicine.
A particularly bad testimony is given to cognitive behavioral therapy, which
is protected by most health insurance companies. In the hope that the sound
disappears, this therapy only teaches how to deal with everyday life or the
displacement of the sound. This is of course past the patient's needs but
cheap. Over the years, the tinnitus tone gets louder at most patients and
thus this displacement strategy has reached the expiration date and the
patient is at the beginning of the next odyssey.
Only Tailor-Made Notched Music Training (TMNMT) in combination with heat
therapy can currently bring relief or healing. The first clinical user
observation of the tinniwell was carried out by Dr. Ebbers in Düren October
2016 to July 2017 in which 30 patients participated. There, 100% healing was
documented after 4 weeks in one patient; on average, all patients had 54%
relief after 4 weeks. A double-blind study on tinniwell will start this
autumn with 60 patients.
By monitoring Resaphene in 250 patients from January 2019 - February 2020, 4
phases of therapy have now been identified. In phase 1, tinnitus becomes
louder during or immediately after treatment. This can only occur after 2
days or 5 weeks. This is the indication that the therapy is working on the
patient. In phase 2, the tinnitus tone drops and becomes quieter. Phase 3 is
a big surprise for the patients because the tinnitus now partially
disappears during the day. In the final phase 4, it also disappears at
night. It is then recommended to continue the therapy for a further 3 weeks
at the last known frequency, since the tinnitus will then permanently
disappear. A premature termination leads to the tinnitus being present in
its old appearance again within a week. Overall, phase 4 was observed after
3-4 months with a daily therapy duration of two hours.
In the past, two studies were carried out at the University of Münster on
the topic of Tailor-Made Notched Music Training. In the second study, the
subjects were advised to stop the therapy if the tinnitus worsened.
According to our knowledge, this was the reason for the poor results from
this study. An improvement in the patient's tinnitus is always preceded by a
worsening.
++ About Resaphene Suisse AG
Resaphene Suisse AG, based in Roggwil, Switzerland, is a medical technology
company that was founded in 2015 and has been selling a tinnitus therapy
device under the name tinniwell since 2016. Resaphene Deutschland GmbH in
Constance and Resaphene UK Ltd. in London and Resaphene US LLC in the US act
as further sales companies.
++ Contact for questions:
Resaphene Suisse AG
Rütistrasse 8b
9325 Roggwil
Switzerland
Contact:
Ms. Anke Rauterkus (Chief Executive Officer)
a.rauterkus@resaphene.ch
End of Media Release
Issuer: Resaphene Suisse AG
Key word(s): Health
2020-05-18 Dissemination of a Press Release, transmitted by DGAP - a service
of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
Language: English
Company: Resaphene Suisse AG
Rütistrasse 8b
9325 Roggwil
Switzerland
Phone: 0041714500668
E-mail: info@resaphene.ch
Internet: www.resaphene.ch
ISIN: CH0367465439
Listed: Foreign Exchange(s) Vienna Stock Exchange
EQS News ID: 1049251
End of News DGAP Media
1049251 2020-05-18
(END) Dow Jones Newswires
May 18, 2020 04:04 ET (08:04 GMT)
© 2020 Dow Jones News
